FAQ/Help |
Calendar |
Search |
Today's Posts |
|
03-10-2017, 09:53 AM | #1 | ||
|
|||
Member
|
|
||
Reply With Quote |
03-10-2017, 07:20 PM | #2 | ||
|
|||
Member
|
For those who might have missed it, the results from the preceding Single Ascending Dose (SAD) trial were published late last year:
First-in-human assessment of PRX 2, an anti–α-synuclein monoclonal antibody, in healthy volunteers - Schenk - 2 16 - Movement Disorders - Wiley Online Library (this is an open-access document) and here is the trial record for the recently-completed Multiple Ascending Dose (MAD) trial: Multiple Ascending Dose Study of PRX 2 in Patients With Parkinson's Disease - Full Text View - ClinicalTrials.gov |
||
Reply With Quote |
"Thanks for this!" says: | anagirl (03-11-2017) |
04-02-2017, 09:04 PM | #3 | ||
|
|||
Junior Member
|
Here's a link to the December 2016 article on PRX002's Phase 1 clinical trial results. My key takeways:
- PRX002 can clear alpha-synuclein from serum (blood) - The trial didn't measure whether it did this in the CNS (i.e.: cross blood-brain barrier) - In mice given a model of PD, they did measure it, and indeed PRX002 did clear alpha-synuclein from the CNS, leading to improvement of PD symptoms - Phase II trial is slated for 2017 --- exciting! - Alpha-synuclein exists in many forms, some healthy, some unhealthy. PRX002 clears them all, but has a preference for aggregates over single molecules. Unclear as to whether the clearing of healthy alpha-synuclein is a problem, though it did not lead to symptoms in the healthy patients in the phase I trial. Still, this is cause for concern. - PRX002 works by binding to alpha-synuclein, apparently in a way that the result can be cleared by the body's own house-cleaning systems (autophagy). This is good, since the alpha-synuclein found in PD cannot be so cleared, hence it builds up. Translating it from unclearable to clearable is a big deal. - It will be exceptionally interesting to see whether this can be proven to be as good in people with PD as it was in mice given fake-PD. With this in mind, as well as other drugs in the pipeline, my focus for my own PD remains squarely with doing whatever I can to slow the progression. For me, this includes: exercise, diet, intermittent fasting, rasagiline (yes, the last one is controversial). -- Dan Darn - I have less than 10 posts, so it won't let me post the link. Would someone please reply to this post, after re-assembling the following link. -- Dan onlinelibrary.wiley.com/ doi/ 10.1002/ mds.26878/ full |
||
Reply With Quote |
"Thanks for this!" says: | jeffreyn (04-02-2017) |
04-02-2017, 09:37 PM | #4 | ||
|
|||
Member
|
Dan,
The link you wanted to post is actually the first link in my post (i.e. the post just above your post). Jeff |
||
Reply With Quote |
04-02-2017, 09:52 PM | #5 | ||
|
|||
Member
|
... and here is a link to the just-announced results of the multiple-ascending-dose (MAD) trial:
Clinical Results Presented from Prothena's Phase 1b Study of PRX2/RG7935 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson's Disease (NASDAQ:PRTA) Quick summary: - the Phase 1 trials were successful; - a global Phase 2 trial of approximately 300 patients with early PD is planned to commence in the second quarter of 2017. Last edited by jeffreyn; 04-03-2017 at 06:11 AM. Reason: Added summary |
||
Reply With Quote |
04-03-2017, 10:27 AM | #6 | ||
|
|||
Junior Member
|
Thanks Jeff. The latter link is the one I meant to paste in. Hopefully, in a couple of years, there will be less of those kind of errors
Dan |
||
Reply With Quote |
"Thanks for this!" says: | jeffreyn (04-03-2017) |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||